Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase
/ genetics
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Disease Management
Female
Gene Rearrangement
Humans
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Oncogene Proteins, Fusion
/ genetics
Prognosis
Protein Kinase Inhibitors
/ administration & dosage
Retrospective Studies
Treatment Outcome
Tumor Burden
Clinical practice
alectinib
anaplastic lymphoma kinase fusion gene mutation
chemotherapy
non-small cell lung cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
01
12
2019
revised:
12
12
2019
accepted:
16
12
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
2
2020
Statut:
ppublish
Résumé
To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation.
PATIENTS AND METHODS
METHODS
We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people.
RESULTS
RESULTS
There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment.
CONCLUSION
CONCLUSIONS
By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.
Identifiants
pubmed: 32014940
pii: 40/2/957
doi: 10.21873/anticanres.14029
doi:
Substances chimiques
Oncogene Proteins, Fusion
0
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
957-964Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.